NEW YORK (GenomeWeb) – Natera today provided preliminary financial guidance for fiscal years 2015 and 2016.
The San Carlos, California-based molecular diagnostic company said it expects 2015 revenues to be in the range of $175 million to $190 million, 10 percent to 20 percent higher than its 2014 revenues of $159.3 million. It said it expects 2016 revenues to be in the range of $220 million to $240 million.
The company went public earlier this month, raising $180 million in an initial public offering on the Nasdaq Global Select Market.
In documents filed today with the US Securities and Exchange Commission, the firm also said it expects R&D costs to be around 15 percent to 18 percent of revenues and SG&A costs to be around 60 percent of revenues.
Natera launched a noninvasive prenatal test, Panorama, in March 2013 and said today that its 2016 revenue estimate "assumes robust adoption and reimbursement of the Panorama test within the general population in 2016."
In 2014, Natera accessioned 185,000 Panorama tests, and in the first quarter of 2015, it ran 55,000 tests. It did not give a full-year 2015 estimate for how many tests it expects to run.
The company is also developing its technology to analyze cell-free DNA from tumors, and Cancer Research UK is using Natera's technology in its 840-patient study called Tracking Cancer Evolution through Therapy (TRACERx).
In early Friday trade, shares of Natera were down 6 percent at $19.21.